Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olinciguat in stable sickle cell disease
NCT03285178Phase 2Completed
- Sponsor
- Cyclerion Therapeutics
- Start
- Dec 2017
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of olinciguat in sickle cell disease (SCD), sponsored by Cyclerion Therapeutics. Started Dec 2017; status: completed.
02
Drugs
olinciguat
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT03285178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03285178.